Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00826280
Recruitment Status : Completed
First Posted : January 22, 2009
Results First Posted : October 21, 2011
Last Update Posted : December 18, 2017
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI

Condition or disease Intervention/treatment Phase
Coronary Artery Disease (CAD) Drug: regadenoson Drug: overencapsulated caffeine Radiation: technetium Drug: placebo Phase 3

Detailed Description:
All subjects will undergo rest and stress scans. Those subjects who qualify by demonstrating at least 1 reversible defect, will undergo a third scan. All stress scans will involve the injection of regadenoson as the pharmacologic stress agent. Prior to the third scan, the subject will be administered blinded capsules of placebo or caffeine.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 347 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson
Actual Study Start Date : March 24, 2009
Actual Primary Completion Date : July 15, 2010
Actual Study Completion Date : July 15, 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Regadenoson

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo plus Regadenoson
Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
 Drug: regadenoson
IV
Other Names:
  • Lexiscan
  • CVT 3146

Radiation: technetium
IV
Other Names:
  • sestamibi
  • tetrafosmin

Drug: placebo
oral
Experimental: Caffeine 200 mg plus Regadenoson
One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
 Drug: regadenoson
IV
Other Names:
  • Lexiscan
  • CVT 3146

Drug: overencapsulated caffeine
oral

Radiation: technetium
IV
Other Names:
  • sestamibi
  • tetrafosmin
Experimental: Caffeine 400 mg plus Regadenoson
Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
 Drug: regadenoson
IV
Other Names:
  • Lexiscan
  • CVT 3146

Drug: overencapsulated caffeine
oral

Radiation: technetium
IV
Other Names:
  • sestamibi
  • tetrafosmin


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Number of Reversible Defects [ Time Frame: Day 3 and Day 5 ]

    Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.

    Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).



Secondary Outcome Measures :
  1. Change in Summed Difference Score (SDS) Across All 17 Segments [ Time Frame: Day 3 and Day 5 ]

    The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).

    Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).

    The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).


  2. Change in Number of Reversible Defects Assessed by Computerized Quantitation [ Time Frame: Day 3 and Day 5 ]

    Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.

    Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).


  3. Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation [ Time Frame: Day 3 and Day 5 ]

    The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).

    Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).

    The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).


  4. Change From Baseline in Heart Rate [ Time Frame: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min) ]

    Baseline is the last non-missing measurement on or before first dose of regadenoson

    Change is calculated as the time point minus baseline.


  5. Change From Baseline in Systolic Blood Pressure [ Time Frame: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min) ]

    Baseline is the last non-missing measurement on or before first dose of regadenoson.

    Change is calculated as the time point minus baseline.


  6. Change From Baseline in Diastolic Blood Pressure [ Time Frame: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min) ]

    Baseline is the last non-missing measurement on or before first dose of regadenoson.

    Change is calculated as the time point minus baseline.



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have undergone a previous diagnostic study [e.g., SPECT, echocardiography, magnetic resonance imaging (MRI), etc.] for a clinical indication demonstrating evidence of reversible defects in ≥ 1 vascular segment, have had other stress testing within the past 3 months, or the subject's history suggests at least a 50% likelihood of CAD

    • If the previous diagnostic study shows only 1 reversible defect and it is in segment 17, another reversible defect will need to be present
  • Subject with CAD must have an intermediate/low-risk for immediate intervention
  • Subject must ingest caffeinated food or beverages regularly (at least the equivalent of one cup of caffeinated coffee daily)
  • Subject must agree to not ingest any caffeine or other foods containing methylxanthine at least 24 hours prior to each study visit
  • Subject must agree to abstain from eating solid food or drinking liquids other than water for at least 30 minutes prior to each study visit and 30 minutes following each study visit

Exclusion Criteria:

  • Subject with documented myocardial infarction (MI) ≤ 30 days prior to enrollment
  • Subject with history of percutaneous coronary intervention (PCI) ≤ 4 weeks prior to enrollment
  • Subject with history of coronary artery bypass graft (CABG) ≤ 8 weeks prior to enrollment
  • Subject has prior history of heart transplantation
  • Subject has unstable angina, known severe left main coronary artery stenosis, severe heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension (systolic blood pressure < 90 or > 180 mmHg, respectively), or > 1st degree atrioventricular block in the absence of a functioning pacemaker
  • Subject requires emergent cardiac medical intervention or catheterization
  • Subject has a history of smoking, regardless of frequency, tobacco type or method of intake, or using any smoking cessation products, including but not limited to the nicotine patch or nicotine gum, within 3 months prior to first dose of regadenoson
  • Subject is currently undergoing treatment with theophylline, or theophylline containing medications within 7 days prior to randomization (Day 3)
  • Subject has a history of known or suspected bronchoconstrictive or bronchospastic lung disease [e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.]
  • Subject has a history of diabetes associated with gastric disorders and/or emptying
  • Subject has end stage renal disease (ESRD) with a GFR< 15mL/min or currently undergoing dialysis for ESRD
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826280


Locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35294
Huntsville, Alabama, United States, 35801
United States, California
La Mesa, California, United States, 91942
Mission Viejo, California, United States, 92691
Roseville, California, United States, 95661
Sacramento, California, United States, 95819
Santa Rosa, California, United States, 95405
United States, Connecticut
Hartford, Connecticut, United States, 06102-5037
United States, Delaware
Newark, Delaware, United States, 19173
United States, Florida
Jacksonville, Florida, United States, 32216
Miami, Florida, United States, 33173
Tamarac, Florida, United States, 33321
United States, Illinois
Aurora, Illinois, United States, 60504
United States, Kansas
Overland Park, Kansas, United States, 66209
United States, Maine
Auburn, Maine, United States, 04210
United States, Massachusetts
Pittsfield, Massachusetts, United States, 01201
United States, Michigan
Detroit, Michigan, United States, 48202
Ypsilanti, Michigan, United States, 48197
United States, Missouri
Kansas City, Missouri, United States, 64111
United States, New York
Albany, New York, United States, 12205
Rochester, New York, United States, 14642-8679
United States, Ohio
Columbus, Ohio, United States, 43214
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19102
Wyomissing, Pennsylvania, United States, 19610
United States, Tennessee
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Layout table for investigator information
Study Director: Use Central Contact Astellas Pharma Global Development
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00826280    
Other Study ID Numbers: 3606-CL-3002
First Posted: January 22, 2009    Key Record Dates
Results First Posted: October 21, 2011
Last Update Posted: December 18, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.
Keywords provided by Astellas Pharma Inc:
pharmacologic stress
ischemia
coronary artery disease (CAD)
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Caffeine
Regadenoson
Central Nervous System Stimulants
 Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Adenosine A2 Receptor Agonists
Purinergic P1 Receptor Agonists
Purinergic Agonists